Measuring BNP Is Unnecessary in Syncope Patients

Including B-type natriuretic peptide levels did not improve accuracy of the Canadian Syncope Risk Score.

Among patients presenting with syncope, serum concentrations of circulating B-type natriuretic peptides (BNP and NT-proBNP) can be higher in those who experience subsequent serious adverse events (SAEs) than in those without SAEs. The Canadian Syncope Risk Score (CSRS) — the most accurate and validated syncope risk stratification tool available — uses patient history, troponin levels, and electrocardiogram parameters to assist in patient evaluation (NEJM JW Gen Med Nov 1 2016 and CMAJ 2016; 188:289 and NEJM Gen Med May 1 2020 and JAMA Intern Med 2020; 180:737). Investigators studied 1400 adults who presented to six Canadian emergency departments (EDs) with syncope to determine whether adding NT-proBNP to CSRS can improve risk stratification…

Reviewing Author

Daniel D. Dressler, MD, MSc, SFHM, FACP

Disclosures

RoyaltiesMcGraw-Hill; Elsevier

Editorial BoardsMedical Clinics of North America; Caribbean Medical Journal International Advisory Panel (2021–2026)

Daniel D. Dressler, MD, MSc, SFHM, FACP

Disclosures

RoyaltiesMcGraw-Hill; Elsevier

Editorial BoardsMedical Clinics of North America; Caribbean Medical Journal International Advisory Panel (2021–2026)

Measuring BNP Is Unnecessary in Syncope Patients

Topics

Reviewing Author